文献速递甲状腺疾病

伴高细胞特征的甲状腺乳头状癌:介于经典型与高细胞亚型之间的中间实体

Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes.
PubMed 文献 · Thyroid · 2023-04-25

回顾性观察队列分析2005至2020年三级学术转诊中心292例患者(81例高细胞亚型、65例伴高细胞特征、146例经典型),比较临床病理与基因组特征,发现伴高细胞特征者疾病风险介于高细胞亚型与经典型之间,高细胞亚型TERT启动子热点突变多于伴高细胞特征者。

要点

  • 伴高细胞特征甲状腺乳头状癌的疾病特异性风险介于高细胞亚型与经典型之间。
  • 高细胞亚型5年无进展生存率为76.5%,伴高细胞特征为81.5%,经典型为88.3%。
  • 高细胞亚型TERT启动子热点突变比例为44%,伴高细胞特征为6%(p=0.012)。

核心结论

  • 研究显示甲状腺乳头状癌存在疾病特异性风险的连续谱,伴高细胞特征为介于高细胞亚型与经典型之间的中间实体。
  • 这些数据提供了对就诊时风险的更精细理解,并更好地阐明了基因组驱动因素的多样性。

研究设计与样本

  • 回顾性观察队列分析,纳入2005至2020年在三级学术转诊中心连续评估的所有高细胞亚型与伴高细胞特征甲状腺乳头状癌患者,并设经典型甲状腺乳头状癌对比队列。
  • 共分析292例患者:81例高细胞亚型、65例伴高细胞特征、146例经典型。
  • 对部分队列行靶向下一代测序以专门了解高细胞亚型与伴高细胞特征之间的差异。

主要发现

  • 晚期美国癌症联合委员会分期比例:高细胞亚型13% vs 伴高细胞特征8% vs 经典型1%(p=0.002)。
  • 宏观甲状腺外侵犯比例:高细胞亚型38% vs 伴高细胞特征14% vs 经典型12%(p<0.001)。
  • 5年无进展生存率:高细胞亚型76.5% vs 伴高细胞特征81.5% vs 经典型88.3%。
  • 负向复合结局(死亡、进展或需先进治疗)发生率:高细胞亚型40.2% vs 伴高细胞特征20.7% vs 经典型11.2%(p<0.001)。
  • 多变量Cox回归分析中,负向复合结局独立与高细胞亚型相关(HR 4.3,置信区间1.1-16.1,p=0.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: While the diagnosis of papillary thyroid carcinomas (PTCs) with tall cell features (PTCtcf) is often made for carcinomas with histological features intermediate between classic and tall cell subtypes of PTC (tcPTC), its comparative signature to that of either tcPTC or classic PTC is less clear. The objective of this study was to perform an integrative clinicopathologic and genomic analysis elucidating the spectrum of tcPTC, PTCtcf, and classic PTC. Methods: We analyzed all consecutive patients with tcPTC and PTCtcf evaluated at a tertiary academic referral center between 2005 and 2020, as well as a comparative cohort of classic PTC, in a retrospective observational cohort analysis. Clinicopathologic data were compared among the three groups, including progression-free survival (PFS), recurrent/persistent disease, and a negative composite outcome of death, progression, or need for advanced therapy. To specifically understand differences between tcPTC and PTCtcf, targeted next-generation sequencing was performed in a subset of these cohorts. Results: A total of 292 patients were analyzed (81 tcPTC, 65 PTCtcf, 146 classic PTC). Thirteen percent of tcPTC versus 8% of PTCtcf versus 1% of classic PTC had the advanced American Joint Committee on Cancer stage (p = 0.002). Similarly, macroscopic extrathyroidal extension was observed in 38% of tcPTC, 14% of PTCtcf, and 12% of classic PTC (p < 0.001). The 5-year PFS was 76.5%, 81.5%, and 88.3% for tcPTC, PTCtcf, and classic PTC, respectively, while the rates of the negative composite outcome 40.2% for tcPTC, 20.7% for PTCtcf, and 11.2% for classic PTC (p < 0.001). In a multivariable Cox regression analysis, the negative composite outcome was independently associated with tcPTC (HR 4.3 [confidence interval 1.1-16.1], p = 0.03). tcPTC demonstrated substantially more hotspot TERT promoter mutations than PTCtcf (44% vs. 6%, p = 0.012). Conclusions: Our study demonstrates a continuum of disease-specific risk of PTC, pointing at PTCtcf as an intermediate entity between tcPTC and classic PTC. These data provide a more refined understanding of risk at time of presentation, while better elucidating the diversity of genomic drivers.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bikas A, Wong K, Pappa T, et al. Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes. Thyroid. 2023. PMID: 36960703. doi:10.1089/thy.2022.0534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。